BUSINESS BRIEFING
- Share via
Biotech giant Amgen Inc.’s widely used anemia drug Aranesp didn’t benefit patients with chronic kidney disease, Type 2 diabetes and anemia in a large, late-stage study, the company said.
Patients in the study who got Aranesp as part of their treatment fared no better on the study’s two main measures than those who got a placebo. One measure was heart complications or death from any cause; the other was the length of time until the patient died or needed chronic kidney dialysis.
Patients in the Aranesp group also had more strokes, a known risk of the drug.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
